Watch Now: Dr. Christopher Janson: ASGCT Presentation on Myrtelle’s Phase 1/2 Gene Therapy Clinical Trial in Patients with Canavan Disease

Article Date
June 6, 2023

This article is featured on another website.

Go to article

Related posts

Browse all articles
July 14, 2026

Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate

July 14, 2026

Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate

July 9, 2026

Beyond the Biomarkers

July 9, 2026

Beyond the Biomarkers